Market Access: Asia-Pacific

Market Access Services is an established leader in analysis, reimbursement and pricing of health care interventions.

Contact Us

Our Australian-based Market Access consultants form part of a global team based in Sydney, London, Gaithersburg and San Diego. This commercially-focused group draws on more than 100 years of collective experience in health technology assessment including the preparation of over 300 submissions to the PBAC, PTAC, MSAC and other reimbursement agencies. 

Health Technology Assessment and Reimbursement Services

  • Landscape reviews and market access assessments
  • Reimbursement and pricing strategy development
  • Clinician interviews, surveys, and advisory panels and stakeholder research
  • Systematic and targeted literature reviews
  • Reimbursement submissions for drugs, devices and other health care products focused on achieving commercial objectives

Health Economic Modeling

  • Cost-effectiveness and cost-utility models
  • Budget impact analyses and forecasts
  • Cohort and individual patient simulations (e.g., Markov, discrete event, microsimulation)
  • Dynamic models, including infectious diseases
  • Bespoke software applications, including iPad tools

Statistical Services

  • Meta-analyses and meta-regressions
  • Indirect treatment comparisons including Bucher method, Bayesian network analysis and specialised methods using individual patient data
  • Customised trial data analysis
  • Statistical data translation for economic models (e.g. survival extrapolations, utility estimation)

Outcomes Research to Support Reimbursement & Pricing Strategy

  • Observational studies including chart reviews and registries
  • Database analyses including Australian PBS 10% sample
    • Treatment patterns
    • Persistence and adherence
    • Utilisation volumes by patient or prescriber characteristics
    • Survival analysis
  • Utility and willingness-to-pay studies

Meet Labcorp's Australia/APAC Market Access Team

Adam Gordois, Director, Health Economics BA (Hons), MSc Health Econ

Adam Gordois has over 18 years of health economics consulting experience in Australia and the UK spanning the pharmaceutical and medical devices industries, government, and not-for-profit organisations. His areas of special expertise include market access and reimbursement support, healthcare technology and policy assessment, cost-effectiveness modelling and forecasting. Adam has published in and provided peer reviews for a variety of health economics and clinical journals, and from 2006 to 2015 ran the Pharmacoeconomics course of the MMedSc Drug Development program at the University of NSW.

Prior to joining Labcorp Drug Development, Adam was Director of Health Economics and Social Policy at Deloitte Access Economics in Sydney following senior health economics roles at IMS (Australia), and a Research Fellow role at the York Health Economics Consortium, UK. Adam received an MSc in Health Economics (Distinction) from the University of York, and a BA in Business Economics (First Class Honours) from the University of Leicester.

Sam Colman, Director, HEOR, BEc, BSc (Hons), MBiostat

Sam Colman has over 18 years of experience as a statistician in government, academia, and industry, including 11 years in the pharmaceutical industry. He has expertise in several therapeutic areas including oncology, endocrine, neuroscience, cardiovascular disease and respiratory disease. Sam has designed and analysed a significant number of trial types including parallel randomised controlled trials, observational, cross-over, case-control, sample surveys, meta-analyses, and chart audits, and he has experience in all phases of clinical development (Phase I to Phase IV).   

Sam has a strong health economics and outcomes research background with expertise in meta-analysis, indirect comparisons, and area-under-the-curve estimates and has worked on a number of successful PBAC submissions in Australia. Sam received a BEc and a BSc (Honours, Statistics) from the Australian National University and a Masters of Biostatistics from the University of Sydney. 

Dante Kemp, Manager, MSc Biostatistics

Dante Kemp has over 8 years of experience working in health economics and biostatistics. At Labcorp Drug Development, Dante specialises in the development of economic models and the provision of statistical analyses. He manages health economics projects such as reimbursement submissions, evidence based literature reviews, retrospective and prospective collection of outcome and resource data, and pricing analyses. He also conducts statistical analyses including writing of statistical analysis plans, data management in SAS/STATA/Excel/VBA, development of statistical models, clinical trial design, and analysis of clinical trial data.

Prior to joining Labcorp Drug Development in 2018, Dante worked as a statistician at John Wlodarczyk Consulting Services.  His work there included planning and conducting the analysis of clinical trials, writing clinical study reports, developing global economic models, and supporting reimbursement submissions internationally. Dante’s was part of the first successful submission of a co-dependent technology in Australia, and his modelling approach was subsequently the standard in Australia. He has published on the association between cancer and immuno-suppression, and on the predictive factors and outcomes of bleeding complications following coronary intervention. Dante holds a Master’s of Science in Biostatistics from the New Jersey Institute of Technology, and a Bachelor’s of Science in Biochemistry from Rutger’s University.

Oona Reardon, Senior Manager, BSc (Hons), MPH

Oona has several years’ experience in health economics within consulting, academic and industry sectors. Oona’s areas of expertise include critical appraisal of clinical trials, health economic audits of trial protocols, developing budget impact models, sourcing health outcomes and resource data, and undertaking literature reviews. 

Prior to joining Labcorp Drug Development, Oona worked at the Centre for Health Economics Research and Evaluation (CHERE) at the University of Technology Sydney (UTS) as a PBAC submission evaluator, working closely with both the ESC and PBAC Secretariats.  

Oona also has experience in developing MSAC Assessment Reports, PICO confirmations and critiques. Oona’s technical understanding of medical devices and services stems from her background as a Medical Physicist based at Liverpool Hospital’s Cancer Therapy Centre and the PET and Nuclear Medicine Department, Royal Price Alfred Hospital.  Oona has also gained extensive experience in regulatory affairs from working within the pharmaceutical industry including the development of complex regulatory strategies for drug reformulation and split dosing.  She has registered many new medicines and devices with Australia’s TGA and New Zealand’s Medsafe.

Oona received a Master’s of Public Health (Health Economics Major with High Distinction) and a Bachelor of Science (Hons) in Applied Physics from UTS.

Contact Us

Labcorp Drug Development 
Suite 3.02 (Level 3, Building A)
97 Waterloo Road, Macquarie Corporate Centre
Macquarie Park  NSW  2113
Tel: +61 2 8879 2000

Let's start a conversation

Contact Us